{
    "id": 32707,
    "fullName": "ERG rearrange",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ERG rearrange indicates an unspecified rearrangement of the ERG gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2078,
        "geneSymbol": "ERG",
        "terms": [
            "ERG",
            "erg-3",
            "p55"
        ]
    },
    "variant": "rearrange",
    "createDate": "03/05/2020",
    "updateDate": "03/05/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20803,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the presence of ERG rearrangement was not associated with response to Zejula (niraparib) treatment in patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 35334,
                "profileName": "ERG rearrange"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20792,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (NCI 9012) trial, the presence of ERG rearrangement or ETV1 fusion did not predict PSA response rate, measurable disease response rate, or median progression-free survival in patients with metastatic castration-resistant prostate cancer treated with Veliparib (ABT-888), Zytiga (abiraterone), and Prednisone combination therapy (PMID: 29261439; NCT01576172).",
            "molecularProfile": {
                "id": 35334,
                "profileName": "ERG rearrange"
            },
            "therapy": {
                "id": 5913,
                "therapyName": "Abiraterone + Prednisone + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 18044,
                    "pubMedId": 29261439,
                    "title": "Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29261439"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35334,
            "profileName": "ERG rearrange",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}